invoX Pharma CEO Ben Toogood (L) and F-star CEO Eliot Forster

F-star bought out in $161M all-cash deal as Hong Kong's Sino Bio­pharm looks to­ward in­ter­na­tion­al ex­pan­sion

Af­ter more than a decade and a half of chart­ing its own course, F-star Ther­a­peu­tics will now set­tle un­der a new um­brel­la com­pa­ny.

The UK biotech will be ac­quired by in­voX Phar­ma, a sub­sidiary of Hong Kong’s Sino Bio­pharm, in a rough­ly $161 mil­lion all-cash deal, the com­pa­nies an­nounced Thurs­day morn­ing. F-star’s buy­out will val­ue its shares $FSTX at $7.12 apiece, near­ly an 80% pre­mi­um above Wednes­day’s clos­ing price.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.